A proven technology platform.
A new era of personalized oncology.
Built on a decade of technology development, commercial experience and clinical research, BioReperia is advancing its proprietary ZTX® platform from established oncology drug development applications toward personalized cancer treatment.
More cancer treatments than ever.
Still no way to know which one will work for each patient.
Despite major advances in oncology, treatment decisions are still largely based on population averages. Patients may undergo months of ineffective therapy, experiencing unnecessary toxicity while valuable treatment time is lost.
BioReperia is developing a functional approach to bridge this gap, generating patient-specific evidence of how tumours respond to different treatments.
Built through commercial success. Advancing toward personalized oncology.
BioReperia’s proprietary ZTX® platform was developed and commercialized through ZTX® ONCOLEADS, supporting pharmaceutical and biotechnology companies in evaluating new cancer therapies using living zebrafish models. Over the past decade, this commercial activity has driven continuous technology development, generated revenue and established the scientific and operational capabilities that underpin BioReperia today.
Building on this foundation, BioReperia has developed ZTX® PREDICT to bring functional tumour-response testing closer to individual patients. The platform applies the same core technology to patient-derived tumour samples, with the aim of supporting more personalized cancer treatment decisions.
Our next phase focuses on advancing ZTX® PREDICT through prospective clinical validation, regulatory development and preparation for future commercialization, with muscle-invasive bladder cancer as the first priority indication.
2.5 MEUR
Cumulative sales
15 +
Countries served commercially
500+
Patient samples tested with ZTX® PREDICT
2 MEUR
Equity capital raised
A decade of building value
Over the past decade, BioReperia has built and commercialized its proprietary ZTX® platform, establishing international customer relationships, generating extensive experimental and clinical datasets, and developing specialized scientific and operational expertise.
These assets, together with our established laboratory infrastructure and quality management systems, provide a strong foundation for advancing ZTX® PREDICT through clinical validation, regulatory development and future commercialization.
Turning established technology into clinical impact.
With a commercially established technology platform and extensive experience from clinical research, BioReperia is entering its next phase of development. Our focus is on advancing ZTX® PREDICT toward regulatory approval and clinical adoption, with muscle-invasive bladder cancer (MIBC) as our first priority indication.
Clinical validation
Prospective multicentre studies to establish clinical performance and generate evidence for treatment decision support.
Regulatory progression
Advancing the IVDR pathway in Europe while preparing for regulatory expansion into the US.
Commercial scale-up
Building the operational, clinical and commercial capabilities required for future market introduction
Be part of our next chapter
BioReperia is building on a decade of commercial experience, proprietary technology and clinical research to advance functional precision oncology. We welcome investors who see the opportunity to bring this established platform closer to clinical practice and enable a more personalized approach to cancer treatment.